Journal
IMMUNOLOGIC RESEARCH
Volume 70, Issue 2, Pages 174-184Publisher
SPRINGER
DOI: 10.1007/s12026-021-09253-w
Keywords
Wnt5A; Systemic lupus erythematosus; Cutaneous lesions; Biomarker
Categories
Funding
- National Natural Science Foundation of China [81860132, 81670157]
- Natural Science Foundation of Ningxia [2019AAC03176]
- Superior Disciplines Construction Founded Project of Ningxia Medical University [XY201826]
Ask authors/readers for more resources
The study found that concentrations of Wnt5A in plasma and urine were significantly higher in SLE patients compared to healthy controls, particularly in those with active disease. Wnt5A could serve as a potential biomarker for assessing disease activity and severity in SLE patients.
Reliable noninvasive biomarkers are needed to accurately assess disease activity and prognosis in patients with systemic lupus erythematosus (SLE). The purpose of this study was to investigate the clinical relevance of Wnt5A with disease activity and severity with cutaneous involvement in particular in SLE patients; its concentrations in plasma and urine were examined and analyzed. In the cross-sectional study, the clinical relevance of Wnt5A protein was evaluated in both plasma and urine of SLE patients and healthy cohorts using commercial enzyme-linked immunosorbent assays (ELISA). Significantly, more abundances of Wnt5A protein were determined in both of plasmas and urines of SLE patients compared to healthy cohorts (p < 0.0001), which were even higher in active disease (AD) SLE patients relative to low disease activity (LDA) SLE patients (p < 0.0001). Meanwhile, the ROC curve analysis demonstrated that the plasma and urine Wnt5A were potential candidate biomarkers for identifying the disease activity and severity in SLE patients. The discriminant function analysis further revealed that the plasma and urine Wnt5A were separated and distinct for AD SLE patients and healthy controls. In consistence, the disease severity was correlated with the plasma and urine Wnt5A as ascertained by CLASI activity score and the prevalence of serositis in SLE patients. These results suggest that Wnt5A, as a summary measure for different inflammatory processes, could be a potential biomarker for accessing the disease activity, and a noninvasive biomarker for evaluating the disease severity in terms of cutaneous involvement in SLE patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available